Prostate Cancer

News and new technology innovations concerning how imaging technology can help diagnose and treat prostate cancer can be found on this channel.

Professor Samer Ezziddin, M.D., from Saarland University/Saarland University Hospital.

Professor Samer Ezziddin, M.D., from Saarland University/Saarland University Hospital. Image courtesy of Saarland University/Thorsten Mohr

 

News | Prostate Cancer | January 13, 2020
January 13, 2020 — When a non-scientist tries to imagine a scientist, the image that often arises is one of a somewhat...
prostate cancer UCL study
News | Prostate Cancer | January 03, 2020
January 3, 2020 — Nearly one in six deaths from prostate cancer could be prevented if targeted screening was introduced...
Ferrotran (formerly Combidex), based on Ferumoxtran-10, is the only contrast agent which can detect lymph node metastases as small as 2 mm diameter

Ferrotran (formerly Combidex), based on Ferumoxtran-10, is the only contrast agent which can detect lymph node metastases as small as 2 mm diameter. Standard MRI or CT are not able to detect lymph node metastases smaller than 7 – 8 mm. Since most of the oncologic patients are dying due to metastases, a precise diagnostic is of utmost importance. The detection of small metastases, combined with the very clear and contrast rich MRI image of Ferrotran, enables an earlier and more precise treatment. Therefore, Ferrotran gives the patient a much higher chance of recovery.

News | Prostate Cancer | December 24, 2019
December 24, 2019 — SPL Medical announced today that the first patient has been successfully diagnosed with suspected...
Prof. Dr. Samer Ezziddin from Saarland University/Saarland University Hospital.

Prof. Dr. Samer Ezziddin from Saarland University/Saarland University Hospital. Photo courtesy of Thorsten Mohr/Saarland University

News | Prostate Cancer | November 28, 2019
November 28, 2019 — Reports of new cancer treatments often raise high hopes and expectations, particularly, of course,...
 Prostate cancer MRI
News | Clinical Trials | November 15, 2019
November 15, 2019 — Theragnostics, which is developing innovative radiopharmaceuticals to improve cancer diagnosis and...
GE Healthcare and Theragnostics Partnering on PSMA PET/CT Imaging Agent
News | Prostate Cancer | October 16, 2019
October 16, 2019 — GE Healthcare and Theragnostics have entered into a global commercial partnership for a new prostate...
Low four-year rates of gastrointestinal (13.6 percent) and urologic issues (7.6 percent) suggest hypofractionated proton therapy as an alternative to traditional radiotherapy to reduce toxicity.

Low four-year rates of gastrointestinal (13.6 percent) and urologic issues (7.6 percent) suggest hypofractionated proton therapy as an alternative to traditional radiotherapy to reduce toxicity.

Feature | Prostate Cancer | October 16, 2019 | By Jeff Zagoudis
Radiation therapy is an important tool in the clinician’s armamentarium for treatment of localized, early-stage...
Videos | Prostate Cancer | September 30, 2019
Bill Hartsell, M.D., medical director of the Northwestern Medicine Proton Center in Warrenville, Ill., discusses the...
High-dose Radiation Effective for Men Whose Prostate Cancer Has Spread
News | Prostate Cancer | September 23, 2019
September 23, 2019 — A randomized clinical trial of targeted, high-dose radiation for men with oligometastatic prostate...
Long-term Hormone Therapy Increases Mortality Risk for Low-PSA Men After Prostate Surgery
News | Prostate Cancer | September 16, 2019
September 16, 2019 — Secondary analysis of a recent clinical trial that changed the standard of care for men with...
Isoray to Spotlight Cesium-131 Advances at ASTRO Annual Meeting
News | Brachytherapy Systems | September 13, 2019
September 13, 2019 — Isoray Inc. announced it will spotlight the growing cancer treatment applications of Cesium-131...
The irregularly marginated left tumor mass that bulges the lateral capsule appears three times the volume on the multiplanar 3-D/4-D image reconstruction and shows complete extraprostatic extension

Figure 1. 2-D (top) vs 3-D (bottom). The irregularly marginated left tumor mass that bulges the lateral capsule appears three times the volume on the multiplanar 3-D/4-D image reconstruction and shows complete extraprostatic extension. Note: This anterolateral lesion is not clinically palpable.

Feature | Prostate Cancer | September 05, 2019 | By Robert Bard, M.D., DABR, FASLM
Extracapsular extension (ECE) is a major clinical indicator for brachytherapy or external beam treatment of prostate...
Surging Demand for Image-guided, Stereotactic Radiation Therapy Driving Fiducial Marker Growth
News | Radiation Therapy | August 22, 2019
August 22, 2019 — As fiducial markers gain traction in parallel to rising incidences of various cancer affecting lung,...
Videos | Treatment Planning | August 21, 2019
This is an example of the Mirada DLCExpert deep learning software that automatically identifies organs, segments and...
Improved Imaging Technique Could Increase Chances of Prostate Cancer Survival
News | Prostate Cancer | August 20, 2019
August 20, 2019 — According to the American Cancer Society, approximately one in nine men will be diagnosed with...
MRIdian System Limits Early Toxicity for Prostate Cancer Without Implanted Markers
News | Image Guided Radiation Therapy (IGRT) | August 19, 2019
August 19, 2019 — ViewRay Inc. announced the acceptance of publication by the International Journal of Radiation...
Profound Medical Receives U.S. FDA 510(k) Clearance for Tulsa-Pro
Technology | Interventional Radiology | August 16, 2019
August 16, 2019 — Profound Medical Corp. announced it has received 510(k) clearance from the U.S. Food and Drug...
Efficacy of Isoray's Cesium Blu Showcased in Recent Studies
News | Brachytherapy Systems | August 14, 2019
August 14, 2019 — Isoray announced a trio of studies recently reported at scientific meetings and published in medical...
Progenics Pharmaceuticals Collaborating With Veterans Affairs on AI Research Program
News | Artificial Intelligence | July 26, 2019
July 26, 2019 — Oncology company Progenics Pharmaceuticals Inc. announced their collaboration with the Veterans Affairs...
Videos | Artificial Intelligence | July 22, 2019
Leigh Conroy, Ph.D., physics resident, University Health Network, Princess Margaret Cancer Center, Toronto, Canada,...